Key Points
- CFO Stephen Feider sold 744 shares at an average $17 each, worth $12,648. He retained 159,378 shares after the transaction, a 0.46% reduction in his holdings.
- Beta Bionics reported quarterly revenue of $35.51 million and an EPS loss of $0.52, narrowly beating analysts’ loss estimate of $0.53. Analysts expect a full-year loss of $2.04 per share.
- Analyst sentiment is moderately positive: the consensus rating is “Moderate Buy,” with an average price target of $23.69.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) CFO Stephen Feider sold 744 shares of the company's stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $17.00, for a total transaction of $12,648.00. Following the completion of the transaction, the chief financial officer owned 159,378 shares in the company, valued at approximately $2,709,426. This trade represents a 0.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Stephen Feider also recently made the following trade(s):
- On Thursday, November 5th, Stephen Feider sold 382 shares of Beta Bionics stock. The stock was sold at an average price of $17.04, for a total transaction of $6,509.28.
- On Wednesday, September 2nd, Stephen Feider sold 6,675 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25.
Beta Bionics Price Performance
NASDAQ:BBNX opened at $16.51 on Friday. The firm has a 50 day simple moving average of $18.54 and a 200-day simple moving average of $14.85. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.01. The firm had revenue of $35.51 million for the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. As a group, research analysts expect that Beta Bionics, Inc. will post -2.04 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on BBNX shares. Wall Street Zen lowered Beta Bionics from a "hold" rating to a "strong sell" rating in a research note on Saturday, October 31st. Leerink Partners lifted their price objective on Beta Bionics from $24.00 to $27.00 and gave the company an "outperform" rating in a research report on Monday, September 14th. Bank of America upped their target price on Beta Bionics from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Tuesday, September 15th. UBS Group reiterated a "buy" rating and set a $25.00 target price on shares of Beta Bionics in a research report on Tuesday, September 15th. Finally, Jefferies Financial Group started coverage on Beta Bionics in a research note on Monday, October 12th. They issued a "buy" rating and a $30.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $23.69.
Check Out Our Latest Analysis on Beta Bionics
Hedge Funds Weigh In On Beta Bionics
A number of hedge funds have recently made changes to their positions in the stock. Ieq Capital LLC grew its stake in shares of Beta Bionics by 33.9% during the 3rd quarter. Ieq Capital LLC now owns 19,550 shares of the company's stock valued at $371,000 after buying an additional 4,953 shares during the period. Lisanti Capital Growth LLC acquired a new position in Beta Bionics in the third quarter valued at $683,000. Jefferies Financial Group Inc. acquired a new position in Beta Bionics in the third quarter valued at $1,708,000. Commonwealth Equity Services LLC grew its position in Beta Bionics by 34.7% during the third quarter. Commonwealth Equity Services LLC now owns 31,795 shares of the company's stock valued at $603,000 after acquiring an additional 8,196 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Beta Bionics during the second quarter valued at about $2,524,000.
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user's body weight and adjusts insulin delivery based on glucose readings.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
